Journal article
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
Abstract
BACKGROUND: Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency. We aimed to evaluate the effect of ferric carboxymaltose, compared with placebo, on outcomes in patients who were stabilised after an episode of acute heart failure.
METHODS: AFFIRM-AHF was a multicentre, double-blind, randomised trial done at 121 sites in Europe, South America, and …
Authors
Ponikowski P; Kirwan B-A; Anker SD; McDonagh T; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Göhring UM; Keren A
Journal
The Lancet, Vol. 396, No. 10266, pp. 1895–1904
Publisher
Elsevier
Publication Date
12 2020
DOI
10.1016/s0140-6736(20)32339-4
ISSN
0140-6736